What question did this study set out to answer?

The aim is to assess factors influencing immunotherapy access and outcomes in head and neck cancer patients.

Disparate Access and Outcomes of Immunotherapy in Head and Neck Cancer Treatment

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals imbalances in immunotherapy access and survival in head and neck cancer, indicating areas for equitable care improvement.

The aim is to assess factors influencing immunotherapy access and outcomes in head and neck cancer patients.
Analyzed data from 414,380 adults with advanced stage head and neck cancer.
Used multivariable regression to determine factors affecting immunotherapy receipt and timing.
Evaluated overall survival using Cox models considering various clinical and sociodemographic covariates.
Only 4.7% of the cohort received immunotherapy, with significant delays for Black patients and females.
Adjuvant immunotherapy improved survival, while other types of immunotherapy showed worse outcomes when compared to no immunotherapy.
Factors such as Black race, older age, and lower education were associated with higher mortality among immunotherapy recipients.

Byrd et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Analysis reveals imbalances in immunotherapy access and survival in head and neck cancer, indicating areas for equitable care improvement.